DK4084791T3 - Specifikke tryptaminer til brug i behandlingen af humørsvingninger - Google Patents

Specifikke tryptaminer til brug i behandlingen af humørsvingninger Download PDF

Info

Publication number
DK4084791T3
DK4084791T3 DK21711684.7T DK21711684T DK4084791T3 DK 4084791 T3 DK4084791 T3 DK 4084791T3 DK 21711684 T DK21711684 T DK 21711684T DK 4084791 T3 DK4084791 T3 DK 4084791T3
Authority
DK
Denmark
Prior art keywords
tryptamines
treatment
specific
mood
switches
Prior art date
Application number
DK21711684.7T
Other languages
English (en)
Inventor
Andrew Carry Kruegel
Jonathan Sporn
Original Assignee
Gilgamesh Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilgamesh Pharmaceuticals Inc filed Critical Gilgamesh Pharmaceuticals Inc
Application granted granted Critical
Publication of DK4084791T3 publication Critical patent/DK4084791T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK21711684.7T 2020-02-18 2021-02-18 Specifikke tryptaminer til brug i behandlingen af humørsvingninger DK4084791T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062978075P 2020-02-18 2020-02-18
PCT/US2021/018534 WO2021168082A1 (en) 2020-02-18 2021-02-18 Specific tryptamines for use in the treatment of mood disorders

Publications (1)

Publication Number Publication Date
DK4084791T3 true DK4084791T3 (da) 2025-02-03

Family

ID=74871827

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21711684.7T DK4084791T3 (da) 2020-02-18 2021-02-18 Specifikke tryptaminer til brug i behandlingen af humørsvingninger

Country Status (22)

Country Link
US (5) US20220241243A1 (da)
EP (2) EP4084791B1 (da)
JP (4) JP7242969B2 (da)
KR (3) KR20230124103A (da)
CN (2) CN115135320B (da)
AU (2) AU2021224899B2 (da)
BR (1) BR112022016382A2 (da)
CA (1) CA3172046A1 (da)
DK (1) DK4084791T3 (da)
ES (1) ES3014741T3 (da)
FI (1) FI4084791T3 (da)
HR (1) HRP20250148T1 (da)
HU (1) HUE070631T2 (da)
IL (2) IL301235A (da)
LT (1) LT4084791T (da)
MX (2) MX2022010082A (da)
PL (1) PL4084791T3 (da)
PT (1) PT4084791T (da)
RS (1) RS66496B1 (da)
SI (1) SI4084791T1 (da)
SM (1) SMT202500143T1 (da)
WO (1) WO2021168082A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4230195A1 (en) 2019-03-07 2023-08-23 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
EP4084791B1 (en) * 2020-02-18 2024-12-18 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders
EP4146198A4 (en) 2020-05-08 2024-05-15 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
AU2021337466A1 (en) * 2020-09-01 2023-03-30 Enveric Biosciences Canada Inc. Halogenated psilocybin derivatives and methods of using
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
EP4347559A4 (en) * 2021-06-02 2025-04-09 Saint Joseph's University FLUORINATED TRYPTAMINE COMPOUNDS, RELATED ANALOGUES AND METHODS USING THEM
IL311211B1 (en) 2021-09-03 2026-02-01 Alexander Shulgin Res Institute Inc Asymmetric allyl tryptamines
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
EP4423062A4 (en) * 2021-10-29 2025-08-27 Psilera Inc MODIFIED INDOLE COMPOUNDS
WO2023108174A1 (en) * 2021-12-10 2023-06-15 Terran Biosciences, Inc. Analogs of 6-methoxy- n, n-dimethyltryptamine
JP2025501630A (ja) * 2021-12-24 2025-01-22 サイロ プロプライエタリ リミテッド 化合物
EP4457214A4 (en) 2021-12-30 2025-12-03 Atai Therapeutics Inc DIMETHYLTRYPTAMINE ANALOGUES USED AS NITRIC OXIDE ADMINISTRATION MEDICINES
US20250091993A1 (en) * 2022-01-27 2025-03-20 Terran Biosciences Inc. Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
KR20250005177A (ko) * 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 불안 치료를 위한 5-메톡시-n,n-다이메틸트립타민
JP2025531630A (ja) * 2022-08-31 2025-09-24 サイビン アイアールエル リミテッド トリプタミン化合物、組成物、及び使用方法
AU2023383549A1 (en) * 2022-11-17 2025-06-05 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
WO2025000053A1 (en) 2023-06-28 2025-01-02 Psylo Pty Ltd Compounds
EP4735441A1 (en) 2023-06-28 2026-05-06 Psylo Pty Ltd Pyrrolopyridine compounds for the treatment of mental illnesses
US12180158B1 (en) * 2023-08-03 2024-12-31 Gilgamesh Pharmaceuticals, Inc. Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
CN121866243A (zh) * 2023-09-07 2026-04-14 耶路撒冷希伯来大学伊森姆研究发展有限公司 致幻化合物、其制备方法及其用途
WO2025111597A1 (en) * 2023-11-22 2025-05-30 Gilgamesh Pharmaceuticals, Inc. A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB853775A (en) 1957-09-19 1960-11-09 Parke Davis & Co Pharmaceutical compositions and methods for producing phenylcyclohexane compounds
DE1668550A1 (de) 1967-09-19 1971-07-22 Parke Davis & Co 2-Alkoxyalkylamino-2-phenylcyclohexanonverbindungen und ihre Saeure-Additionssalze und Verfahren zu ihrer Herstellung
US4065573A (en) 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
CA1100516A (en) 1976-06-03 1981-05-05 Daniel Lednicer 4-amino-4-arylcyclohexanones and their ketals
CA1105938A (en) 1976-06-03 1981-07-28 Daniel Lednicer 4-amino-4-arylcyclohexanone ketals
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
JP4460446B2 (ja) 2002-06-21 2010-05-12 スベン ライフ サイエンシズ リミティド 治療薬剤として有用なセロトニン受容体親和性を有する新規の四環系アリールカルボニル・インドール、その製造方法、並びにそれらを含む医薬組成物
RU2320663C2 (ru) 2002-06-21 2008-03-27 Сувен Лайф Сайенсиз Лимитед Новые арилалкилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции
AU2003249582B2 (en) 2002-06-21 2006-08-03 Suven Life Sciences Limited Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2618888A1 (en) 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
EP1956016A1 (en) 2006-12-15 2008-08-13 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
AR073841A1 (es) 2008-03-27 2010-12-09 Gruenenthal Chemie Hidroximetilciclohexilaminas, medicamentos y uso de los mismos para la fabricacion de medicamentos.
JP2012514655A (ja) 2009-01-09 2012-06-28 プレジデント アンド フェローズ オブ ハーバード カレッジ フッ素含有化合物およびその使用法
US20120122948A1 (en) 2009-05-27 2012-05-17 Universite Libre De Beuxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
CN104276993B (zh) 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
WO2018064465A1 (en) * 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
CA3052974A1 (en) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
GB201808150D0 (en) 2018-05-18 2018-07-11 Small Pharma Ltd Therapeutic compounds
GB201716942D0 (en) 2017-10-16 2017-11-29 Small Pharma Ltd Therapeutic compounds
EP3713568A1 (en) 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Combination product for the treatment of neurological and/or psychiatric disorders
EP3505509A1 (en) 2017-12-29 2019-07-03 Université de Liège Methods for the preparation of arylcycloalkylamine derivatives
CN118453559A (zh) 2018-02-15 2024-08-09 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CN110343050B (zh) 2018-04-04 2021-09-24 上海键合医药科技有限公司 芳香类化合物及其制备方法和用途
KR102104953B1 (ko) 2018-04-17 2020-04-27 삼육대학교 산학협력단 신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도
TW202026281A (zh) 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
EP4230195A1 (en) 2019-03-07 2023-08-23 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
CN115190815B (zh) 2019-12-26 2024-06-18 吉尔伽美什制药公司 芳基环己基胺衍生物及其在精神障碍的治疗中的用途
EP4084791B1 (en) * 2020-02-18 2024-12-18 Gilgamesh Pharmaceuticals, Inc. Specific tryptamines for use in the treatment of mood disorders
AU2021337466A1 (en) * 2020-09-01 2023-03-30 Enveric Biosciences Canada Inc. Halogenated psilocybin derivatives and methods of using
CN112174851A (zh) 2020-11-09 2021-01-05 广州万孚生物技术股份有限公司 一种氟胺酮半抗原、氟胺酮抗原及其制备方法和应用
CN113234036B (zh) 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Also Published As

Publication number Publication date
CN115135320A (zh) 2022-09-30
JP7242969B2 (ja) 2023-03-20
IL295536B2 (en) 2023-08-01
EP4084791B1 (en) 2024-12-18
KR20230124103A (ko) 2023-08-24
US20220041551A1 (en) 2022-02-10
US11440879B2 (en) 2022-09-13
CN115135320B (zh) 2023-08-29
EP4501407A2 (en) 2025-02-05
PT4084791T (pt) 2025-01-24
JP2026034471A (ja) 2026-02-27
NZ790704A (en) 2024-12-20
LT4084791T (lt) 2025-02-25
US20260055059A1 (en) 2026-02-26
HRP20250148T1 (hr) 2025-04-11
EP4084791A1 (en) 2022-11-09
MX2022010082A (es) 2022-11-14
US20240351983A1 (en) 2024-10-24
AU2021224899B2 (en) 2025-02-27
EP4501407A3 (en) 2025-04-23
CN117503759A (zh) 2024-02-06
AU2021224899A1 (en) 2022-08-25
HUE070631T2 (hu) 2025-06-28
IL295536A (en) 2022-10-01
JP2025071254A (ja) 2025-05-02
JP7640600B2 (ja) 2025-03-05
MX2024006123A (es) 2024-06-04
SMT202500143T1 (it) 2025-05-12
JP2023504308A (ja) 2023-02-02
KR20260008838A (ko) 2026-01-16
CA3172046A1 (en) 2021-08-26
KR20220129054A (ko) 2022-09-22
IL301235A (en) 2023-05-01
PL4084791T3 (pl) 2025-04-22
SI4084791T1 (sl) 2025-04-30
IL295536B1 (en) 2023-04-01
KR102567903B1 (ko) 2023-08-18
WO2021168082A1 (en) 2021-08-26
AU2025201184A1 (en) 2025-03-13
BR112022016382A2 (pt) 2022-10-25
US20240317683A1 (en) 2024-09-26
RS66496B1 (sr) 2025-03-31
US20220241243A1 (en) 2022-08-04
FI4084791T3 (fi) 2025-03-08
JP2023063360A (ja) 2023-05-09
ES3014741T3 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
IL295536A (en) Specific tryptamines for use in the treatment of mood disorders
DK4303583T3 (da) Csf1r-inhibitorer til anvendelse til behandling af tenosynoviale kæmpecelletumorer
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer
DK3496739T3 (da) Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
EP3565846A4 (en) PROTEIN THERAPEUTICS FOR THE TREATMENT OF SENESCENT CELLS
DK3998261T3 (da) Pyrimidin-2-ylamino-1h-pyrazoler som lrrk2-inhibitorer til brug i behandlingen af neurodegenerative lidelser
DK3675854T3 (da) Piperidinyl-indolderivativer til anvendelse ved behandling af c3-glomerulopati
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
DK3962601T3 (da) 5-HT2A-agonister til anvendelse til behandling af depression
DK4076461T3 (da) Lumateperon til brug ved behandling af skizofreni
EP3496733C0 (en) COMPOSITION FOR USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
DK4005570T3 (da) Pridopidin til anvendelse behandling af retts syndroe
DK3576738T3 (da) Gaboxadolmonohydrat i behandling af tinnitus
IL290348A (en) Surface treatment compositions and methods
DK3997032T3 (da) Behandling og rensning af carbonholdige materialer
EA201791937A1 (ru) Противовоспалительные полипептиды
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
DK3490625T3 (da) Indretning med struktureret belægning til brug som implantat til behandling af perforeringer i trommehinden
PL3850113T3 (pl) Markery przydatne w strategiach wzbogacania przy leczeniu choroby zwyrodnieniowej stawów
DK4419526T3 (da) Heterocykliske forbindelser til anvendelse i behandlingen af cancer
DK4340842T3 (da) Sotorasib til anvendelse ved behandling af kræft
EP3946606C0 (en) BICYCLIC JAK INHIBITORS AND THEIR USES
EP4355238A4 (en) ELECTROPORATION TREATMENT
DK4125911T3 (da) Obicetrapib til behandling af demens